膀胱癌根治性膀胱切除术前膀胱内免疫治疗(INVEST)试验方案
INVEST 是一项英国开放标签、非随机、单中心 Ib 期剂量递增机会窗研究,评估阿替利珠单抗经膀胱内被动灌注或直接注射(黏膜下)在拟行根治性膀胱切除术的膀胱癌患者中的安全性和初步活性。主要终点为剂量限制性毒性和不良事件,次要终点包括无进展生存、病理完全缓解率和治疗依从性。
要点
- INVEST 试验探索阿替利珠单抗膀胱内给药在根治性膀胱切除术前膀胱癌患者中的安全性。
- 给药途径包括被动灌注和直接注射(黏膜下),剂量为 600 mg 或 1200 mg,单次或多次(每周 3-6 周)。
- 主要终点为剂量限制性毒性和不良事件,次要终点包括无进展生存、病理完全缓解率和治疗依从性。
核心结论
- INVEST 试验旨在评估膀胱内阿替利珠单抗在根治性膀胱切除术前膀胱癌患者中的安全性和初步活性。
研究设计与样本
- 英国开放标签、非随机、单中心 Ib 期剂量递增机会窗研究,纳入拟行根治性膀胱切除术的各分期膀胱癌患者。
- 两种给药途径(被动灌注和直接注射)均设初始剂量确认阶段确定毒性和推荐剂量,随后剂量扩展阶段进一步评估推荐剂量的安全性和毒性。
关键数值与推荐
- 阿替利珠单抗经膀胱内被动灌注或直接注射(肿瘤/膀胱壁)给药,队列接受 600 mg 或 1200 mg 剂量,单次或多次(每周 3-6 周)。
- 主要终点包括剂量限制性毒性和不良事件;次要终点包括无进展生存、病理完全缓解率和治疗依从性。
- 探索性终点包括药代动力学特征(预定时间点血清和尿液浓度)、成像质谱分析根治性膀胱切除组织中阿替利珠单抗分布的空间分析以及总生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-risk non-muscle-invasive bladder cancer (HRNMIBC) has a variable prognosis, managed predominantly by local surgical resection and intravesical Bacillus Calmette-Guérin (BCG), or radical cystectomy (RC). Current treatments are poorly tolerated, have supply limitations and often fail to control the disease. Treatments overcoming these limitations are needed to improve HRNMIBC outcomes. Many novel agents have been approved in recent years (including systemic pembrolizumab, nogapendekin alfa inbakicept-pmln, N-803), but long-term efficacy is unknown. Given advanced bladder cancer findings, we believe direct intravesical administration of atezolizumab may aid with managing HRNMIBC or muscle-invasive bladder cancer in patients who are ineligible for cisplatin-based neoadjuvant chemotherapy. STUDY DESIGN: The INtraVESical immunoTherapy (INVEST) trial is a UK-based, open-label, non-randomised, single-centre, Phase Ib dose escalation, window of opportunity study exploring atezolizumab administration via intravesical routes (passive instillation and direct injection [sub-urothelial]) in patients with bladder cancer with all stages undergoing RC. For both routes, an initial dose confirmation stage will determine toxicity and recommended atezolizumab dosage, followed by a dose expansion stage to further evaluate safety and toxicity at the recommended dose. ENDPOINTS: We aim to investigate safety (primary) and preliminary activity (secondary) of intravesical atezolizumab delivered by passive instillation and direct injection into the tumour/bladder wall in patients with bladder urothelial cell carcinoma prior to RC. Primary endpoints include dose limiting toxicities and adverse events. Secondary endpoints include progression-free survival, pathological complete response rate and treatment compliance. Exploratory endpoints include pharmacokinetic profile (assessed by serum and urine concentrations at prespecified timepoints), spatial analysis of atezolizumab distribution within RC tissue by imaging mass spectrometry and overall survival. PATIENTS AND METHODS: Atezolizumab will be administered intravesically by either passive instillation or direct injection into the tumour/bladder wall. Cohorts will receive either 600 mg or 1200 mg doses administered as a single dose or as multiple doses (weekly for 3-6 weeks). TRIAL REGISTRATION: International Standard Randomised Controlled Trial Number: ISRCTN15842444, registered 2 December 2022.
引用
- Lister-Whelan R, Senior E, Kendall J, et al. INtraVESical immunoTherapy (INVEST) prior to radical cystectomy for bladder cancer: trial protocol. BJU Int. 2026. PMID: 42515859. doi:10.1111/bju.70387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。